C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis.

dc.contributor.author

Mulligan, Jennifer K

dc.contributor.author

Patel, Kunal

dc.contributor.author

Williamson, Tucker

dc.contributor.author

Reaves, Nicholas

dc.contributor.author

Carroll, William

dc.contributor.author

Stephenson, Sarah E

dc.contributor.author

Gao, Peng

dc.contributor.author

Drake, Richard R

dc.contributor.author

Neely, Benjamin A

dc.contributor.author

Tomlinson, Stephen

dc.contributor.author

Schlosser, Rodney J

dc.contributor.author

Atkinson, Carl

dc.date.accessioned

2023-10-17T18:32:58Z

dc.date.available

2023-10-17T18:32:58Z

dc.date.issued

2018-09

dc.date.updated

2023-10-17T18:32:58Z

dc.description.abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease with an unknown etiology. Recent studies have implicated the complement system as a potential modulator of disease immunopathology. We performed proteomic pathway enrichment analysis of differentially increased proteins, and found an enrichment of complement cascade pathways in the nasal mucus of individuals with CRSwNP as compared to control subjects. Sinonasal mucus levels of complement 3 (C3) correlated with worse subjective disease severity, whereas no significant difference in systemic C3 levels could be determined in plasma samples. Given that human sinonasal epithelial cells were the predominate sinonasal source of C3 and complement anaphylatoxin 3a (C3a) staining, we focused on their role in in vitro studies. Baseline intracellular C3 levels were higher in CRSwNP cells, and following exposure to Aspergillus fumigatus (Af) extract, they released significantly more C3 and C3a. Inhibition of complement 3a receptor (C3aR) signaling led to a decrease in Af-induced C3 and C3a release, both in vitro and in vivo. Finally, we found in vivo that C3aR deficiency or inhibition significantly reduced inflammation and CRS development in a mouse model of Af-induced CRS. These findings demonstrate that local sinonasal complement activation correlates with subjective disease severity, and that local C3aR antagonism significantly ameliorates Af-induced CRS in a rodent model.

dc.identifier

S1933-0219(22)00581-5

dc.identifier.issn

1933-0219

dc.identifier.issn

1935-3456

dc.identifier.uri

https://hdl.handle.net/10161/29276

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Mucosal immunology

dc.relation.isversionof

10.1038/s41385-018-0048-x

dc.subject

Nasal Mucosa

dc.subject

Cell Line

dc.subject

Epithelial Cells

dc.subject

Animals

dc.subject

Mice, Inbred BALB C

dc.subject

Humans

dc.subject

Mice

dc.subject

Aspergillus fumigatus

dc.subject

Rhinosporidiosis

dc.subject

Nasal Polyps

dc.subject

Disease Models, Animal

dc.subject

Chronic Disease

dc.subject

Inflammation

dc.subject

Receptors, Complement

dc.subject

Proteome

dc.subject

Signal Transduction

dc.subject

Complement C3

dc.title

C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis.

dc.type

Journal article

duke.contributor.orcid

Patel, Kunal|0000-0001-8079-520X

pubs.begin-page

1375

pubs.end-page

1385

pubs.issue

5

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Surgery

pubs.organisational-group

Surgery, Cardiovascular and Thoracic Surgery

pubs.publication-status

Published

pubs.volume

11

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis.pdf
Size:
527.06 KB
Format:
Adobe Portable Document Format